With FDA Clinical Hold Lifted, Idenix Hopes To Combine Its “Nuc” With A Protease Inhibitor For HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
Idenix’s IDX184 is the only unpartnered nucleoside polymerase inhibitor for hepatitis C in clinical development. With an FDA hold lifted, the company wants to make quick progress testing ‘184 in interferon-free regimens for HCV.